focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Narrows Loss, Agrees Sale Of US Unit For Up To USD19 million

Thu, 27th Sep 2018 10:44

LONDON (Alliance News) - Midatech Pharma PLC reported a narrowed interim loss as it planned to divest its US unit to become a "pure play biotech company".

Total revenue for the six months to June 30 rose to GBP549,000 from GBP473,000 as the company's pretax loss narrowed slightly to GBP6.5 million from GBP6.7 million a year earlier.

Research & development costs rose to GBP4.6 million from GBP4.2 million, as administrative costs fell to GBP2.1 million from GBP2.7 million.

Looking ahead, the company said the year promises to be an "important foundation for unlocking and delivering" the full potential of its technology platforms and programmes. Clinical data is expected on three programmes, for carcinoid cancer, brain cancer, and its autoimmune diabetes vaccine.

Separately, the company said it has agreed to sell Midatech Pharma US Inc to Kanwa Holdings LP, an affiliate of Barings LLC, for up to USD19 million.

Of this sale price, USD13 million will be paid as initial consideration and up to USD6 million based on the unit's net sales performance in 2018 and 2019.

Net proceeds from the sale will be used to fund key research & development priorities, said Midatech Pharma, such as the MTD201 Q-Octreotide and MTX110 programmes toward their next development milestones, as well as repay an outstanding loan to MidCap Financial.

Midatech Pharma Chief Executive Craig Cook said: "The divestment of Midatech's US commercial arm will allow us to streamline and reshape the business from a specialty pharma to a pure play biotech company, and focus all our energy, attention and resources on advancing our innovative, higher value R&D oncology pipeline."

For 2017, Midatech Pharma US contributed GBP6.7 million in net statutory revenue and GBP3.9 million towards the group's pretax loss.

The sale is subject to shareholder approval at a general meeting.

Shares in Midatech Pharma were down 9.1% at 25.00 pence on Thursday.

More News
23 Apr 2018 11:02

Midatech Pharma 2017 Loss Narrows On Costs And Impairments Fall

LONDON (Alliance News) - Midatech Pharma PLC said Monday its 2017 loss narrowed on lower costs and reduced impairments as its approaches 2018 with a number of key "inflection" points for

Read more
15 Mar 2018 12:36

Midatech Pharma CEO Phillips To Step Down, COO Cook Steps Up

LONDON (Alliance News) - Pharmaceutical firm Midatech Pharma PLC said Thursday its Chief Executive Jim Phillips will leave the company after five years at the who is departing

Read more
22 Nov 2016 13:29

Midatech Pharma receives upfront access fee

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma said it has received an upfront technology access fee and option payment of £450,000. This was under the terms of the exclusive licence granted to Emergex Vaccines Ltd. This licence covered the use of Midatech's prop

Read more
15 Nov 2016 12:04

Midatech Pharma chooses MTR104 for liver cancer treatment

(ShareCast News) - International speciality pharmaceutical company Midatech Pharma has selected its candidate compound MTR104 to take into a formal IND-enabling programme during 2017. This would be followed by human studies planned for 2018, the company said. "The programme is focused on advanced l

Read more
31 Oct 2016 09:39

BROKER RATINGS SUMMARY: HSBC Raises IAG To Hold From Reduce

Read more
11 Oct 2016 10:30

Midatech To Raise GBP14 Million Via Placing And Open Offer (ALLISS)

Read more
30 Sep 2016 08:41

Midatech Says Trials Of Drug Using Its Gold Nanoparticles Commence

Read more
2 Sep 2016 12:07

Midatech Pharma's revenues increases due to US sales

(ShareCast News) - Midatech Pharma's half-year revenues increased significantly, with management sounding an optimistic note regarding the potential of the company´s research and development programmes. For the six months ended 30 June, revenue increased significantly to £3.8m from £320,000 in the s

Read more
7 Jul 2016 09:05

Midatech-Cardiff University Collaboration Gets Diabetes Grant

Read more
27 Jun 2016 11:29

Midatech Pharma Issues Final Shares To Settle Q Chip Acquisition (ALLISS)

Read more
18 May 2016 09:39

Midatech Signals Further Focus On "Better Suited" Oncology Treatments

Read more
11 May 2016 08:49

Midatech Pharma Trading Ahead Of Expectations On Strong Revenue Growth

Read more
26 Apr 2016 09:27

Midatech Pharma Gets Positive Data From Q-Octreotide Trial

Read more
21 Apr 2016 07:55

Midatech Pharma Sees Positive Dosing Data In Uveitis Programme

Read more
13 Apr 2016 08:24

Midatech Loss Widens On Acquisition Costs, But Revenue Surges

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.